Patient Advocacy
On July 1, 2021, 28 patient advocacy groups submitted a letter demonstrating their support for H.R. 2815, also known as the Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act, which aims to increase Medicare reimbursement for health systems that prescribe biosimilars to patients.
Cancer remains one of the costliest diseases to treat in the United States.
Cancer remains one of the costliest diseases to treat in the United States.
On August 20, 2021, a group of 16 organizations representing patients, consumers, providers, and taxpayers published an open letter to officials from the Centers for Medicare & Medicaid Services and the Department of Health and Human Services asking them to consider enacting a zero copay policy for Medicare Part B patients, a move the groups said would improve access to biosimilars and save seniors in Medicare as much as $3 billion in out-of-pocket costs.
Results 1 - 4 of 4
